PubMed HealthSearch

PubMed · 3351689

Improving pulmonary function does not decrease oxygen consumption in infants with bronchopulmonary dysplasia.

Abstract

To determine whether the high oxygen consumption VO2 in infants with bronchopulmonary dysplasia (BPD) is caused by increased mechanical power of breathing, and if improvement of pulmonary mechanics would reduce mechanical power of breathing and VO2 we gave 16 infants with oxygen-dependent BPD at 19.5 +/- 10.7 (mean +/- SD) weeks of age placebo, theophylline, and orally administered diuretics or theophylline plus diuretics. Pulmonary mechanics, mechanical power of breathing, and VO2 were measured at the beginning and end of each study period. In the placebo group, all infants had elevated VO2 (7.4 +/- 1.4 mL/kg/min) and carbon dioxide production (6.6 +/- 1.2 mL/kg/min), increased airway resistance (59 +/- 30 cm H2O/L/sec), decreased dynamic compliance (0.073 +/- 0.024 mL/cm H2O/cm), increase respiratory rate (52 +/- 11), and increased mechanical power of breathing (2.22 +/- 1.05 kg.cm/kg/min). Treatment with theophylline, diuretics, and theophylline plus diuretics resulted in a significant improvement in pulmonary mechanics and mechanical power of breathing, but not in VO2. These results suggest that the increased VO2 in infants with BPD is not secondary to increased mechanical power of breathing.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L C Kao, D J Durand, B G Nickerson. 1988. Improving pulmonary function does not decrease oxygen consumption in infants with bronchopulmonary dysplasia.. https://doi.org/10.1016/s0022-3476(88)80184-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Inositol supplementation in premature infants with respiratory distress syndrome.

BACKGROUND: Inositol influences cellular function and organ maturation. Feeding premature infants inositol-rich breast milk increases their serum inositol concentrations. Whether inositol supplementation benefits infants receiving fluids for parenteral nutrition, which are inositol-free, is not known. METHODS: We carried out a placebo-controlled, randomized, double-blind trial to determine the effects of administering inositol (80 mg per kilogram of body weight per day) during the first five days of life to 221 infants with respiratory distress syndrome who were receiving parenteral nutrition (gestational age, 24 to 32 weeks; birth weight, less than 2000 g). All the infants were treated with mechanical ventilation and some with surfactant as well. The primary end point was survival at 28 days without bronchopulmonary dysplasia. RESULTS: The 114 patients given inositol had significantly lower mean requirements for inspiratory oxygen (P less than 0.01) and mean airway pressure (P less than 0.05) from the 12th through the 144th hour of life than did the 107 infants given placebo. Eighty-one infants given inositol and 51 given placebo survived without bronchopulmonary dysplasia (71 vs. 55 percent; P = 0.005). In the 65 infants given surfactant, however, inositol had no effect on the degree of respiratory failure. Thirteen infants given inositol and 21 given placebo had retinopathy of prematurity (13 vs. 26 percent; P = 0.022); none of the infants given inositol had stage 4 disease, whereas 7 of those given placebo did (0 vs. 9 percent; P = 0.012). Among the infants given placebo, those who had poor outcomes (death, bronchopulmonary dysplasia, or stage 4 retinopathy of prematurity) had lower serum inositol concentrations during days 2 through 7 than those who had good outcomes (P less than 0.01). CONCLUSIONS: The administration of inositol to premature infants with respiratory distress syndrome who are receiving parenteral nutrition during the first week of life is associated with increased survival without bronchopulmonary dysplasia and with a decreased incidence of retinopathy of prematurity.

Bronchopulmonary Dysplasia

[Ureaplasma urealyticum in newborn and premature infants. Its association with bronchopulmonary dysplasia].

Tests for the possible presence of Ureaplasma urealyticum (U. u.), a type of Mycoplasma transmitted perinatally, were performed on 53 consecutive mature newborns and a group of 108 predominantly premature infants. Standard microbiological tests were performed on smears from throat, nose and ear, as well as from vagina or anus. U. u. was isolated from 15 of the 53 mature newborns (28%): none of the children was ill. In the premature group the microorganism was isolated from 13 of the 108 infants (12%). Isolation was the more frequent the smaller the birth weight and the shorter the gestational period. The carrier rate was 50% (6 of 12) in those with birth weights under 1,500 g and a gestational period of less than 29 weeks. In all 6 newborns under 1,500 g who carried U. u. bronchopulmonary dysplasia developed, but in only 2 of the 9 in whom U. u. was not isolated. Administration of erythromycin (20-45 mg/kg.d intravenously) improved the clinical course of 3 of the 5 affected with bronchopulmonary dysplasia. The results demonstrate that U. u. is of significance in perinatal medicine and should be considered especially in the treatment of premature infants requiring artificial ventilation.

Bronchopulmonary Dysplasia